Detalles de la búsqueda
1.
Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI.
Stroke
; 50(11): 3004-3012, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31558144
2.
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
Int J Cancer
; 145(5): 1346-1357, 2019 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30807645
3.
In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.
Gastric Cancer
; 21(3): 401-412, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28852882
4.
BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
Int J Cancer
; 140(2): 449-459, 2017 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27699769
5.
Inhibitor of NFκB Kinase Subunit 2 Blockade Hinders the Initiation but Aggravates the Progression of Crescentic GN.
J Am Soc Nephrol
; 27(7): 1917-24, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26574045
6.
The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.
Exp Dermatol
; 23(8): 579-84, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24942196
7.
Doxorubicin-induced activation of NF-κB in melanoma cells is abrogated by inhibition of IKKß, but not by a novel IKKα inhibitor.
Exp Dermatol
; 21(4): 301-4, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22320445
8.
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Mol Cancer Ther
; 19(1): 26-38, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31582533
9.
Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.
J Med Chem
; 63(15): 8025-8042, 2020 08 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32338514
10.
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
Mol Cancer Ther
; 7(2): 391-7, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18245668
11.
Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/ßcatenin pathway in xenograft models of hepatocellular carcinoma.
Int J Oncol
; 54(3): 1123-1133, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30747223
12.
Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models.
J Nucl Med
; 60(9): 1293-1300, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30850485
13.
Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α-Ketoglutarate.
Cell Rep
; 27(3): 820-834.e9, 2019 04 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-30995479
14.
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Clin Cancer Res
; 25(15): 4723-4734, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31064781
15.
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo.
Clin Cancer Res
; 25(4): 1404-1414, 2019 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30429199
16.
Product-related research: how research can contribute to successful life-cycle management.
Drug Discov Today
; 13(9-10): 457-63, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18468564
17.
Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.
Oncotarget
; 9(75): 34103-34121, 2018 Sep 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-30344925
18.
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.
Cancer Cell
; 31(1): 64-78, 2017 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28073005
19.
Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.
Mol Cancer Ther
; 16(5): 893-904, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28292941
20.
Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.
Clin Cancer Res
; 23(15): 4335-4346, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28364014